# ANRS EP 47 VISCONTI - VISCONTI cohort : International-Viro-Immunologic Sustained CONtrol after Treatment Interruption

Head :Saez-Cirion Asier

Last update : 10/25/2017 | Version : 3 | ID : 8455

## General

### Identification

| | |
|---|---|
| Detailed name | VISCONTI cohort : International-Viro-Immunologic Sustained CONtrol after Treatment Interruption |
| Sign or acronym | ANRS EP 47 VISCONTI |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL approval |

### General Aspects

| | |
|---|---|
| Medical area | Immunology<br>Infectious diseases |
| Health determinants | Iatrogenic<br>Medicine |
| Keywords | primary infection, HIV treatment, functional remission, genetic characteristics, seropositivity, immune system, HIV |

### Scientific investigator(s) (Contact)



| | |
|---|---|
| Name of the director | Saez-Cirion |
| Surname | Asier |
| Address | 25-28 RUE DU DOCTEUR ROUX 75015 PARIS |
| Email | asier.saez-cirion@pasteur.fr |
| Organization | ANRS - Institut |



### Collaborations

| | |
|---|---|
| Participation in projects, networks and consortia | Yes |

| Funding | |
|---|---|
| Funding status | Public |
| Details | ANRS |
| **Governance of the database** | |
| Sponsor(s) or organisation(s) responsible | ANRS - AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES |
| Organisation status | Public |
| Presence of scientific or steering committees | Yes |
| **Additional contact** | |
| Name of the contact | Hocqueloux |
| Surname | Laurent |
| Email | laurent.hocqueloux@chr-orleans.fr |
| Organization | CENTRE HOSPITALIER RÉGIONAL D'ORLÉANS |
| **Main features** | |
| **Type of database** | |
| Type of database | Study databases |
| Study databases (details) | Cohort study |
| Database recruitment is carried out by an intermediary | A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study | No |
| **Database objective** | |
| Main objective | I-VISCONTI is a multicenter, multidisciplinary (clinicians, virologists, immunologists and epidemiologists) pathophysiologic study designed to explore the virological and immunological mechanisms responsible for sustained control of HIV-1 infection after ART interruption in adults or children who started treatment very early in the primary infection or during the chronic phase. I-VISCONTI also aims to identify markers that could |

| | |
|---|---|
| | be used to identify patients who could reasonably interrupt their antiretroviral treatment. |
| Inclusion criteria | Patients infected with HIV-1 and not co-infected with HIV-2<br>- Whatever is the age at the time of HIV-1-infection<br>- Plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy<br>- Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot), at the time of delivery for children or during the chronic phase of infection, and maintained for at least 12 months in both cases.<br>- Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be <400 copies/mL |
| **Population type** | |
| Age | Early childhood (2 to 5 years)<br>Childhood (6 to 13 years)<br>Adolescence (13 to 18 years)<br>Adulthood (19 to 24 years)<br>Adulthood (25 to 44 years)<br>Adulthood (45 to 64 years) |
| Population covered | Sick population |
| Pathology | Z21 - Asymptomatic human immunodeficiency virus [HIV] infection status |
| Gender | Male<br>Woman<br>Other |
| Geography area | International |
| Detail of the geography area | Metropolitan France. |
| **Data collection** | |
| **Dates** | |

| | |
|---|---|
| Date of first collection (YYYY or MM/YYYY) | 2013 |
| **Size of the database** | |
| Size of the database (number of individuals) | < 500 individuals |
| Details of the number of individuals | 14 patients (primary infection). |
| **Data** | |
| Database activity | Current data collection |
| Type of data collected | Clinical data<br>Biological data |
| Clinical data (detail) | Direct physical measures<br>Medical registration |
| Biological data (detail) | Blood test. |
| Presence of a biobank | Yes |
| Contents of biobank | Whole blood<br>Plasma<br>Blood cells isolated<br>DNA |
| Details of biobank content | Consult the scientist in charge. |
| Health parameters studied | Health event/morbidity<br>Health event/mortality<br>Health care consumption and services |
| Care consumption (detail) | Hospitalization<br>Medical/paramedical consultation<br>Medicines consumption |
| **Procedures** | |
| Participant monitoring | Yes |
| Details on monitoring of participants | 7.5 years. |
| Links to administrative sources | No |
| **Promotion and access** | |
| **Promotion** | |

| | |
|---|---|
| Link to the document | http://www.ncbi.nlm.nih.gov/pubmed/?term=ANRS+AND+visconti |
| Description | List of publications in Pubmed |

| Access | |
|---|---|
| Terms of data access (charter for data provision, format of data, availability delay) | PLOS PATHOGENS publication. |
| Access to aggregated data | Access on specific project only |
| Access to individual data | Access on specific project only |